MedTrace Logo

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

NCT01492881 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-05-11

No results posted yet for this study

Summary

The purpose of this research study is to determine how multiple myeloma responds when the study drug vorinostat is added to the standard treatment of bortezomib and pegylated liposomal doxorubicin (PLD). After participants complete the three drug combination and if their multiple myeloma has decreased, the investigators also want to learn what effects (both good and bad) when vorinostat and bortezomib are given to people with multiple myeloma over a longer period of time. This type of treatment is called 'Maintenance Therapy'.

Conditions

Interventions

DRUG

Vorinostat

Oral, 400mg, taken days 4 through 11 of each cycle.

DRUG

Bortezomib

subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle

DRUG

pegylated liposomal doxorubicin

Intravenous, 30mg/m2, Day 4

Sponsors & Collaborators

Principal Investigators

  • Peter M Voorhees, MD · Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-01-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01492881 on ClinicalTrials.gov